TRVN · Trevena Inc

-

Please sign in to comment on TRVN

1 Comment

Admin

4 years, 1 month ago

Trevena, Inc is currently in a long term downtrend where the price is trading 26.1% below its 200 day moving average.

From a valuation standpoint, the stock is 94.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 78.2.

Trevena, Inc's total revenue rose by 122.6% to $69K since the same quarter in the previous year.

Its net income has dropped by 84.2% to $-12M since the same quarter in the previous year.

Finally, its free cash flow fell by 5.2% to $-7M since the same quarter in the previous year.

Based on the above factors, Trevena, Inc gets an overall score of 2/5.

ISIN	US89532E1091
Sector	Healthcare
Industry	Biotechnology
Exchange	NASDAQ
CurrencyCode	USD

Target Price	5
Beta	0.86
Market Cap	1M
PE Ratio	None
Dividend Yield	None

ABOUT

Trevena Inc

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

TRVN · Trevena Inc

-

Trevena Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Trevena Inc using a moving average strategy